At 22, a young person’s world should be filled with possibilities—a career to build, places to travel, friendships to make, and a future to imagine. Instead, this young man, David, was diagnosed with T-cell acute lymphoblastic leukemia/lymphoma (T-cell ALL/LBL).

Overnight, his priorities changed. Life became about survival. Would the treatment work? Would he reach remission? Would he survive? Chemotherapy became his new reality. Alongside multiple chemotherapy medications came corticosteroids such as prednisone or dexamethasone—powerful and important components of ALL treatment.

The goal was clear: destroy the cancer and save his life.

And in many ways, it worked. He achieved remission. But while the cancer was being attacked, another battle was quietly beginning. His bones were paying a price.

The Battle Nobody Was Watching

One serious complication associated with intensive ALL treatment is osteonecrosis, also known as avascular necrosis. Osteonecrosis occurs when blood flow to bone becomes impaired, causing bone tissue to die. As the condition progresses, the bone can weaken and collapse, potentially destroying the joint.

For a young adult, the consequences can be devastating. The same person who fought cancer may suddenly struggle to walk, climb stairs, exercise, work, sleep without pain, attend school, or live independently.

This raises an uncomfortable question:

If we save a patient’s life but leave them unable to live the life they fought for, have we truly finished treating the patient?

When “Just a Side Effect” Isn’t Just a Side Effect

During chemotherapy, pain and fatigue can easily become part of the background. Aches may be blamed on treatment. Weakness may be attributed to chemotherapy. Joint pain may be considered another consequence of steroids. But sometimes the body is trying to tell us something.

Persistent or unexplained bone and joint pain should not automatically be dismissed as a routine side effect.

Hip, knee, ankle, shoulder, or other joint pain—particularly in young patients receiving substantial corticosteroid exposure—deserves careful evaluation. Osteonecrosis can begin subtly. By the time symptoms become severe, significant structural damage may already have occurred. MRI can detect osteonecrosis earlier than conventional X-rays and can be an important diagnostic tool when symptoms raise concern. The lesson is simple:

Listen to the patient. Investigate early. Don’t wait for irreversible damage.

Cancer Is Not the Only Disease We Need to Treat

This story highlights a larger challenge in modern medicine. When someone enters a cancer center, the primary question naturally becomes: Is the cancer responding to treatment? That question is essential—but it cannot be the only question.

A truly holistic approach asks: What is happening to the patient’s bones? What is happening to the heart and endocrine system? What is happening to mental health and mobility? What will this person’s quality of life look like five, ten, twenty, or thirty years from now? The patient is not simply a collection of cancer cells.

The patient is a human being whose entire body is experiencing treatment.

The Price of Survival

Osteonecrosis can be a significant complication in younger patients receiving intensive ALL therapy, particularly those exposed to corticosteroids. One reported cohort of 367 patients with a median age of 23 found osteonecrosis in 17% of patients over five years, with an even higher cumulative incidence among those younger than 30.

Behind every percentage is a person. Behind every MRI is a person. Behind every hip or shoulder replacement is a person.

And behind every cancer survivor is a life that deserves not merely to be prolonged, but to be lived.

The Goal Should Be Both

This is not an argument to simply stop steroids. Corticosteroids are important components of ALL treatment, and changing effective leukemia therapy without careful medical consideration could increase the risk of relapse. The real challenge is more difficult: How do we fight cancer without losing sight of the rest of the human being?

That means bringing hematology/oncology, orthopedics, radiology, physical therapy, rehabilitation, and other specialists together when complications emerge. It means monitoring bone and joint symptoms throughout treatment, investigating persistent pain early, protecting mobility, balancing cancer-control benefits against long-term toxicity, and building survivorship care into treatment from day one. Most importantly, it means listening.

A 22-year-old knows when his body has changed. If he says, “My hip hurts every morning. I can’t walk like I used to. I can’t climb stairs. The pain is getting worse,” those statements should trigger attention—not dismissal.

Proactive medicine means acting before damage becomes irreversible, not simply treating the damage after it happens.

A New Definition of “Cure”

For this young man, defeating T-cell ALL/LBL was the first victory. But it should not have been the final goal.

He should have the opportunity to walk without debilitating pain, study, work, exercise, travel, build relationships, pursue his ambitions, and live independently. Instead, after the enormous financial and emotional cost of cancer treatment, he now faces multiple orthopedic surgeries, including shoulder and hip replacements.

This is not about blame. It is about asking whether earlier recognition, monitoring, and multidisciplinary intervention might have changed the trajectory. Modern medicine has become extraordinarily good at treating cancer. But survival alone cannot be the finish line. A cure should mean more than eliminating cancer. It should mean giving the survivor the best possible chance to reclaim their life.

The questions we ask must evolve: Did we treat the disease? What did the treatment do to the person?

And ultimately, what kind of life did we give back to them? This is the promise of truly holistic cancer care:

Fight cancer. Protect the body. Preserve function. Listen to the patient. Anticipate complications. Coordinate care. And never lose sight of the human being behind the diagnosis.

For a 22-year-old cancer survivor, remission should not mark the end of the journey.

It should mark the beginning of getting his life back.

Disclaimer: This article is based on a true story and is intended for education and awareness, strictly not medical advice. Osteonecrosis during ALL treatment is complex. Treatment decisions should be made by the patient’s oncology and specialist teams based on the individual’s disease, treatment protocol, risks, and clinical circumstances.